drugset / Trial / NCT01876251
A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer
Open-labelTreatment
Summary
This study is aimed to determine the tolerability of the PF-03084014 plus docetaxel combination in patients with advanced breast cancer. Preliminary information about the efficacy of the combination will also be collected.
Timeline
- Start
- 2013-11-04
- Primary completion
- 2015-12-24
- Completion
- 2015-12-24
Outcome
Outcome not reported
Stopped (Business): “The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development. There were no safety/efficacy concerns behind the decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Nirogacestat | Small molecule | 10 mg | Oral |
| Subject | Nirogacestat | Small molecule | 50 mg | Oral |
| Subject | Nirogacestat | Small molecule | 100 mg | Oral |